Given that not only TGF-β interacted with all other 5 molecules based on the above agnostic analysis, but also the potential clinical application of TGF-β inhibitors in cancer immunotherapy combination treatment, we investigated the role of TGF-β signaling pathway in immunotherapy treatment responses in our cohort. The gene discussed is TGFB1; the disease is cancer.